G
Guido Kroemer
Researcher at Institut Gustave Roussy
Publications - 1546
Citations - 294816
Guido Kroemer is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Programmed cell death & Apoptosis. The author has an hindex of 236, co-authored 1404 publications receiving 246571 citations. Previous affiliations of Guido Kroemer include Karolinska Institutet & Spanish National Research Council.
Papers
More filters
Journal ArticleDOI
Pre-processed caspase-9 contained in mitochondria participates in apoptosis
Paola Costantini,J-M Bruey,Maria Castedo,Didier Métivier,Markus Loeffler,Santos A. Susin,Luigi Ravagnan,Naoufal Zamzami,Carmen Garrido,Guido Kroemer +9 more
TL;DR: Bcl-2-mediated regulation of mitochondrial membrane permeabilization may contribute to apoptosis control by preventing mitochondrial, pre-processed caspase-9 from interacting with its cytosolic activators.
Journal ArticleDOI
JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice
Xinxin Song,Shan Zhu,Yangchun Xie,Jiao Liu,Lingyi Sun,Dexing Zeng,Pengcheng Wang,Xiaochao Ma,Guido Kroemer,David L. Bartlett,Timothy R. Billiar,Michael T. Lotze,Herbert J. Zeh,Rui Kang,Daolin Tang +14 more
TL;DR: JTC801 was found to induce a pH-dependent form cell death (alkaliptosis) in cancer cells but not normal cells, and compared gene and protein expression levels between human pancreatic cancer tissues and patient survival times using online R2 genomic or immunohistochemistry analyses.
Journal Article
Apoptosis induction by the photosensitizer verteporfin: identification of mitochondrial adenine nucleotide translocator as a critical target.
Anne-Sophie Belzacq,Etienne Jacotot,Helena L. A. Vieira,Dominique Mistro,David J. Granville,Zhihua Xie,John C. Reed,Guido Kroemer,Catherine Brenner +8 more
TL;DR: It is reported that the photosensitizer verteporfin kills lymphoma cells by an apoptotic process involving a dissipation of the mitochondrial inner transmembrane potential (deltapsim) and belongs to a class of clinically used chemotherapeutic agents acting on PTPC and ANT.
Journal ArticleDOI
The mitochondrial ribosomal protein of the large subunit, Afo1p, determines cellular longevity through mitochondrial back-signaling via TOR1
Gino Heeren,Mark Rinnerthaler,Peter Laun,Phyllis von Seyerl,Sonja Kössler,Harald Klinger,Stefanie Jarolim,Birgit Simon-Nobbe,M. Hager,Christoph Schüller,Didac Carmona-Gutierrez,Lore Breitenbach-Koller,Christoph Mück,Pidder Jansen-Dürr,Alfredo Criollo,Guido Kroemer,Frank Madeo,Michael Breitenbach +17 more
TL;DR: In this paper, the authors present a new long-lived yeast deletion mutation,afo1 (for aging factor one), that confers a 60% increase in replicative lifespan.
Journal ArticleDOI
Trial watch: Dendritic cell-based anticancer therapy
Norma Bloy,Jonathan Pol,Fernando Aranda,Alexander M.M. Eggermont,Isabelle Cremer,Wolf Hervé Fridman,Jitka Fucikova,Jérôme Galon,Eric Tartour,Radek Spisek,Madhav V. Dhodapkar,Laurence Zitvogel,Guido Kroemer,Lorenzo Galluzzi +13 more
TL;DR: Recent advances in the preclinical and clinical development of DC-based anticancer therapeutics are summarized.